Stockscreener 앱 받기
42.96
0.59%
0.25
시장 영업 전:
41.01
-1.95
-4.54%
전일 마감가:
$42.71
열려 있는:
$43.14
하루 거래량:
17,102
Relative Volume:
0.38
시가총액:
$234.48M
수익:
-
순이익/손실:
$-7.12M
주가수익비율:
-18.68
EPS:
-2.3
순현금흐름:
$-6.82M
1주 성능:
+11.99%
1개월 성능:
+7.40%
6개월 성능:
+718.29%
1년 성능:
+6,697%
1일 변동 폭
$42.19
$44.45
1주일 범위
$35.50
$44.45
52주 변동 폭
$0.3438
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
명칭
Monopar Therapeutics Inc
전화
(847) 388-0349
주소
1000 SKOKIE BLVD SUITE 350, WILMETTE
MNPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
42.96 | 234.48M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-19 | 재개 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Piper Sandler | Overweight |
| 2024-10-11 | 개시 | Rodman & Renshaw | Buy |
| 2021-01-28 | 개시 | ROTH Capital | Buy |
Monopar Therapeutics Inc 주식(MNPR)의 최신 뉴스
(MNPR) Investment Analysis - news.stocktradersdaily.com
Monopar Therapeutics Inc. acquired worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. for approximately $110 million. - marketscreener.com
(MNPR) Long Term Investment Analysis - news.stocktradersdaily.com
Major Shareholder Sells Big Chunk of Monopar Therapeutics Stock! - TipRanks
Monopar Therapeutics CEO Robinson sells $1.17 million in stock By Investing.com - Investing.com Canada
HC Wainwright Issues Negative Forecast for MNPR Earnings - Defense World
Jones Trading Reiterates “Hold” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World
What is HC Wainwright’s Forecast for MNPR FY2029 Earnings? - Defense World
Monopar Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks
We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth - Yahoo Finance
Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from HC Wainwright - Defense World
Top 5 Small-cap Biotech Stocks of 2025 - Nasdaq
Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN
Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating - TipRanks
Buy Rating for Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Outlook - TipRanks
Monopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last year - TipRanks
Monopar Therapeutics sees cash runway through December 31, 2026 - TipRanks
Monopar Therapeutics Inc. (MNPR) reports earnings - Quartz
Monopar Therapeutics SEC 10-K Report - TradingView
Monopar Secures 2-Year Runway with $60M War Chest, Advances Wilson Disease Drug - Stock Titan
MNPR Stock Price and Chart — NASDAQ:MNPR - TradingView
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going - Yahoo Finance
Piper Sandler Reaffirms “Overweight” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World
Monopar Therapeutics (MNPR) to Release Quarterly Earnings on Thursday - Defense World
Monopar a new overweight at Piper Sandler on rare disease asset - Seeking Alpha
Piper Sandler sets Monopar stock at $76 with Overweight rating - Investing.com
Buy Rating for Monopar Therapeutics Inc. Driven by Strategic Acquisition and ALXN1840 Potential - TipRanks
Piper Sandler sets Monopar stock at $76 with Overweight rating By Investing.com - Investing.com UK
(MNPR) Trading Report - news.stocktradersdaily.com
Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 19% loss last week hit both individual investors who own 33% as well as institutions - Simply Wall St
Monopar Therapeutics: Strong Data, But There Are Risks (NASDAQ:MNPR) - Seeking Alpha
Monopar Therapeutics appoints new CFO - Investing.com
Monopar Therapeutics Appoints Quan Vu as New CFO - TipRanks
Monopar Therapeutics Inc Says On Feb 28, CFO Karthik Radhakrishnan'S Employment Terminated - Marketscreener.com
Monopar Therapeutics appoints new CFO By Investing.com - Investing.com Australia
Monopar Therapeutics appoints new board member - Investing.com
Monopar Therapeutics appoints new board member By Investing.com - Investing.com UK
Monopar Therapeutics Appoints Lavina Talukdar to Board - TipRanks
Trend Tracker for (MNPR) - Stock Traders Daily
Copper wired: Monopar to electrify Wilson disease? - BioWorld Online
Q1 EPS Estimate for Monopar Therapeutics Raised by Analyst - MarketBeat
Learn to Evaluate (MNPR) using the Charts - Stock Traders Daily
Brookline Capital Management Forecasts MNPR Q1 Earnings - Defense World
Monopar's Incredible Journey From $5 To $50 In Less Than 5 Months - RTTNews
Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 - MSN
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
What's Going On With Cancer-Focused Monopar Therapeutics Stock Today? - MSN
Monopar Therapeutics Inc (MNPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.00%
자본화:
|
볼륨(24시간):